Resonance Health Completes Design and Testing of MRI Muscle Volume and Quality Endpoint

Manish Choudhary

11 November 2026 12:32 PM AEDT

Resonance Health Completes Design and Testing of MRI Muscle Volume and Quality Endpoint

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Resonance Health Ltd (ASX:RHT) has announced the completion of design and testing of its MRI muscle volume and quality endpoint for use in clinical trials, marking what the company describes as an important milestone in its MRI endpoint development strategy.

Key Points

Design and testing of Resonance Health's MRI muscle volume and quality endpoint is complete, developed at customers' request as part of the company's MRI endpoint acceleration programme
The endpoint reports five mid-thigh metrics: intramuscular fat fraction (IMFF), intermuscular adipose tissue (IMAT) volume, muscle volume, fat-free (contractile) muscle volume, and subcutaneous adipose tissue (SAT) volume
The endpoint will be offered to clinical trial customers as an investigational endpoint, subject to completion of software verification and validation activities in line with the company's ISO 13485 quality management system
Sponsors of obesity and metabolic trials will be able to obtain liver fat, visceral and subcutaneous fat, and muscle volume and quality from one MRI session analysed centrally using Resonance's core laboratory

MRI Muscle Endpoint Metrics and Measurement Methodology

Measurements are derived from axial chemical-shift-encoded (Dixon) MRI images acquired across approximately 10 cm of the mid-thigh and analysed centrally by the company's ISO 13485 core lab. The endpoint assesses an extended anatomical region rather than a single image slice to provide a more representative evaluation of muscle composition and quality. Four of the five reported metrics are also expressed as percentages, described as normalised values useful for cross-sectional comparison between participants, while absolute measures may be more informative for assessing longitudinal treatment effects. The thigh is identified in the filing as the leading anatomical site for muscle measurement in pharmaceutical obesity clinical trials.

Intramuscular Fat Fraction Measured Using HepaFatScan Technology

The intramuscular fat fraction (IMFF) metric is measured as a proton density fat fraction (PDFF) using the technology underlying the company's regulatory-cleared HepaFatScan®. The filing states the muscle composition analysis demonstrates excellent repeatability, accuracy, and robustness across all reported metrics. The MRI Muscle Endpoint is described as an investigational endpoint for use in clinical trials only and is not cleared for clinical diagnostic use in any jurisdiction. It expands the company's existing portfolio of quantitative MRI biomarkers, which already includes liver fat (PDFF), liver iron concentration (LIC), liver stiffness (MR elastography), and visceral and subcutaneous adipose tissue measurements.

Single MRI Session to Deliver Combined Endpoint Data for Trial Sponsors

According to the filing, with the MRI Muscle Endpoint, a sponsor can schedule a single MRI session for a participant and receive liver fat, liver iron, visceral and subcutaneous adipose tissue, and muscle volume and quality data from one ISO 13485-certified core laboratory. The endpoint was developed at customers' request and forms part of the MRI endpoint acceleration programme outlined in the company's investor presentation released on 27 October 2026. The filing notes that as at March 2026, 951 obesity and overweight trials were listed on ClinicalTrials.gov, and clinical trial sponsors are increasingly requesting a single imaging protocol reporting liver PDFF, VAT, SAT, muscle volume, and intramuscular fat together.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.